TMCnet News
Bharat Book Bureau: PharmaPoint: HIV - Global Drug Forecast and Market Analysis to 2022 Event Driven Update(M2 PressWIRE Via Acquire Media NewsEdge) Summary Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance. Highlights Key Questions Answered - What are the key antiretroviral agents that are used in the 7MM, Brazil and China? - What do key opinion leaders think of newly marketed and pipeline drugs? - Will the newly approved STRs steal market share from the current gold standard, Atripla? - Which pipeline drugs are going to shape the market landscape during the forecast period of 2012 . (c) 2014 M2 COMMUNICATIONS [ Back To TMCnet.com's Homepage ] |